Developmental Therapeutics

Solid Tumors

VAR0168
Phase I/IIb
CPI-005 +/- CPI-444 and +/- Pembrolizumab
In Advanced Cancers
PI: Kummar Pending

VAR0144
Phase I
VX-970 in
Combo w/ Topoisoerase Inhibitor Tripterase in Patients w/ Advanced Solid Tumors
PI: Kummar Corvus Pharmaceuticals

VAR0143
Phase I/II
ICOS Agonist mAb JTX-2011 +/- Nivolumab in Advanced Refractory Solid Tumor Malignancies
PI: Kummar Jounce Therapeutics

VAR0146
Phase I
Anti-C4.4a Antibody Drug Conjugate BAY 1129980 in Advanced Solid Tumors Known to Express C4.4a
PI: Kummar Bayer HealthCareAG

VAR0129
Phase I/IIa
PI X8394 in Patients with Advanced, Unresectable Solid Tumors
PI: Kummar Plexxicon

VAR0129
Phase II a
Part 2: BRAF Activating Mutation
PI: Kummar Bayer HealthCareAG

VAR0130
Phase I
Dose Escalation Trial of Hu5F9-G4 in Advanced Solid Tumors
PI: Kummar Pfizer

VAR0130
Phase II
Part 2: ovarian cancer or target expressing non small cell lung cancer
PI: Kummar Bayer HealthCareAG

VAR0148
Phase I
MGD009 in Unresectable/Metastatic 87-H3-Expressing Neoplasms
PI: Kummar MacroGenics

VAR0152
Phase IIIi of EDO-S101 in Advanced Solid Tumors
PI: Kummar Pending

NTRK Fusion-Positive Tumors

VAR0154
Phase II
TRK Inhibitor LOXO-195 in Adult and Pediatric Previously Treated NTRK Fusion Cancers
PI: Kummar Loxo Oncology

VAR0136
Phase II
Basket Study of the Oral TRK Inhibitor LOXO-101 in NTRK Fusion-Positive Tumors
PI: Kummar Loxo Oncology

IDH 1/2 Mutant Tumors

VAR0167
Phase II PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
PI: Bui Pending

KEY
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu